ArticleBMC biotechnology2026
Immunoinformatics-guided design of a multi-epitope vaccine targeting WISP1 for gastric cancer.
Article in BMC biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGastric cancer remains a leading cause of cancer-related mortality worldwide, and effective preventive or therapeutic vaccines are still lacking. WNT1‑inducible signalling pathway protein 1 (WISP1/CCN4) is a secreted matricellular protein that is overexpressed in gastric tumours and associated with poor prognosis, making it a promising immunotherapy target. We aimed to design a multi‑epitope protein vaccine candidate targeting WISP1 using an immunoinformatics workflow.
resultsWe predicted linear B‑cell epitopes from WISP1 and filtered them for antigenicity, non-allergenicity, and non-toxicity. High‑scoring MHC class I and class II T‑cell epitopes with broad HLA coverage were then selected. The final construct combined validated B‑ and T‑cell epitopes with appropriate linkers and a TLR‑agonist adjuvant to enhance immunogenicity. Physicochemical profiling indicated that the construct is stable, soluble, hydrophilic and antigenic, with no predicted allergenicity or toxicity. Secondary and tertiary structures were modelled, refined and validated, revealing proper folding and favourable stereochemical quality. Molecular docking showed strong binding to innate immune receptors, particularly TLR4, and molecular dynamics simulations confirmed stable receptor-vaccine interactions with low structural deviation. Binding‑free energy analysis further supported these results. Immune simulations predicted robust primary and secondary immune responses characterised by sustained IgG/IgM production, increased IFN‑γ and IL‑2, and activation of memory B and T cells. Codon optimisation and in‑silico cloning suggested feasibility for experimental expression.
conclusionsThese results indicate that the proposed WISP1 multi‑epitope vaccine is antigenic, safe, structurally stable and capable of eliciting broad humoral and cellular immune responses in silico. This work provides a testable candidate for experimental validation and highlights secreted CCN family proteins as novel targets for gastric cancer vaccines.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.